Skip to main content

Advertisement

Log in

Effect of erythropoiesis-stimulating agents on hemoglobin level, fatigue and hospitalization rate in renal palliative care patients

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objectives

To investigate the effect of erythropoiesis-stimulating agents (ESAs) on hemoglobin (Hb) level, fatigue and hospitalization rate in renal palliative care (PC) patients.

Method

A retrospective cohort study was done between April 2011 and January 2013 in renal palliative care clinic of clustered hospitals in Hong Kong. The study participants included end-stage renal patients (CrCl < 15 ml/h) decided not for dialysis (ESA 39 patients; control 31 patients). From healthcare databases, we retrieved the patient demographics, laboratory results, reasons and time of hospitalizations during the study period. Fatigue was measured by Edmonton Symptom Assessment Scale.

Results

Most were elderly patients and about half of patients had underlying diabetes mellitus. Baseline mean Hb levels were similar (7.57 ± 0.97 g/dL for ESA vs 7.77 ± 0.72 g/dL for control). Mean Hb was raised significantly after 3 and 6 months of ESA injections (9.42 and 9.40 g/dL respectively, P < 0.05). Fatigue was reduced significantly at 3 and 6 months after treatment (P = 0.006 and P = 0.017 respectively). All-cause hospitalization was reduced significantly and there was a trend toward reduction in red blood cell transfusion requirement in the ESA group (P = 0.084).

Conclusion

This study demonstrated that use of ESAs in renal PC was effective and might help in reducing fatigue and hospitalizations rate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. KDOQI (2007) Clinical practice guideline and clinical practice recommendations for anaemia in chronic kidney disease: 2007 update of haemoglobin target. Am J Kidney Dis 50:471–530

    Google Scholar 

  2. Afssaps (2005) Traitement de l’anémie au cours de’insuffisance rénale chronique de l’adulte: recommandations de l’Afssaps. Nephrol Ther 1:S1–S48

  3. European Medicines Agency (EMEA) (2007) Public statement. Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease. 23 October 2007. Doc ref: EMEA/496188/2007. http://www.emea.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500015604.pdf. Accessed 12 Jun 2012

  4. Locatelli F, Aljama P, Canaud B et al., On behalf of the Anaemia (2010) Working Group of European renal best practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce cardiovascular Events with Aranesp Therapy (TREAT) study. Nephrol Dial Transpl 25:2846–2850

    Google Scholar 

  5. Murtagh FE, Addington-Hall J, Higginson IJ (2007) The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 14(1):82–99

    Article  PubMed  Google Scholar 

  6. Yong DS, Kwok AO, Wong DM et al (2009) Symptom burden and quality of life in end-stage renal disease: a study of 179 patients on dialysis and palliative care. Palliat Med 23(2):111–119

    Article  CAS  PubMed  Google Scholar 

  7. Murtagh FE, Addington-Hall JM, Higginson IJ (2011) End-stage renal disease: a new trajectory of functional decline in the last year of life. J Am Geriatr Soc 59(2):304–308

    Article  PubMed  Google Scholar 

  8. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2(4):279–335

    Google Scholar 

  9. Lau F, Downing GM, Lesperance M, Shaw J, Kuziemsky C (2006) Use of Palliative performance scale in end-of-life prognostication. J Palliat Med 9(5):1066–1075

    Article  PubMed  Google Scholar 

  10. Davison SN, Jhangri GS, Johnson JA (2006) Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int 69(9):1621–1625

    Article  CAS  PubMed  Google Scholar 

  11. Teresa González M, Ramos R, Vera M et al (2013) Monthly CERA treatment maintains stable hemoglobin levels in routine clinical practice of peritoneal dialysis patients. Renal Fail 35(3):314–319

  12. Cody J, Daly C, Campbell M et al (2005) Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 3:CD003266

    Google Scholar 

  13. Sánchez-Fructuoso A, Guirado L, Ruiz JC et al (2010) Anemia control in kidney transplant patients treated with methoxy polyethylene glycol-epoetin beta (Mircera): the Anemiatrans Group. Transpl Proc 42:2931–2934

    Article  Google Scholar 

  14. Bader Al-Khalaf, Nour Al-Khalaf, Seham Mustafa (2012) Effect of ethnicity on erythropoietin therapy response for hemodialysis patients: a retrospective study. Hemodialysis Int. doi:10.1111/j.1542-4758.2012.00763

    Google Scholar 

  15. Johansen KL, Finkelstein FO, Revicki DA et al (2012) Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transpl 27(6):2418–2425

    Article  CAS  Google Scholar 

  16. Levin A, Djurdjev O, Barrett B (2001) Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 38:1398–1407

    Article  CAS  PubMed  Google Scholar 

  17. Palazzuoli A, Silverberg DS, Iovine F et al (2007) Effects of berythropoietin treatment on left ventricular remodelling systolic function and B-type natriuretic peptide levels in patients with cardiorenal anemia syndrome. Am Heart J 645:e10–e15

    Google Scholar 

  18. Sarac Erdal, Chikyarappa Anand, Sabol Brian et al (2006) Clinical outcomes associated with conversion from Epoetin alfa to Darbepoetin alfa in Hospitalized hemodialysis patients. Am J Nephrol 26:571–578

    Article  PubMed  Google Scholar 

  19. Locatelli F, Pisoni RL, Akizawa T et al (2004) Anemia management for hemodialysis patients: kidney disease outcomes quality initiative (K/DOQI) guidelines and dialysis outcomes and practice patterns study (DOPPS) findings. Am J Kidney Dis 44:27

    Article  PubMed  Google Scholar 

  20. Pisoni RL, Bragg-Gresham JL, Young EW et al (2004) Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 44:94

    Article  PubMed  Google Scholar 

  21. Frimat L, Mariat C, Landais P et al (2013) Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (CohorteMircera patients non-dialysés), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis. BMJ Open 3:e001888. doi:10.1136/bmjopen-2012-001888

Download references

Acknowledgments

The authors would like to thank all medical and nursing staff of both Grantham Hospital and Tung Wah Hospital for their advice and support in taking care of renal palliative care patients in our study.

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kwok-Ying Chan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chan, KY., Li, CW., Wong, H. et al. Effect of erythropoiesis-stimulating agents on hemoglobin level, fatigue and hospitalization rate in renal palliative care patients. Int Urol Nephrol 46, 653–657 (2014). https://doi.org/10.1007/s11255-014-0661-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-014-0661-x

Keywords

Navigation